PRESTIGE CONSUMER HEALTHCARE INC. Treasury Stock, Common, Value
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) had Treasury Stock, Common, Value of $441.96 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:TreasuryStockCommonValue · last filed 2026-08-06
- 2026-06-30: Treasury Stock, Common, Value $441.96M.
- 2026-03-31: Treasury Stock, Common, Value $439.30M.
- 2025-12-31: Treasury Stock, Common, Value $438.55M.
- 2025-09-30: Treasury Stock, Common, Value $392.23M.
| Period end | Treasury Stock, Common, Value |
|---|---|
| 2026-06-30 | $441.96M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $439.30M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $438.55M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $392.23M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $316.33M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $277.21M 10-K · filed 2026-05-14 |
| 2024-12-31 | $265.84M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $263.50M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $251.57M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $219.62M 10-K · filed 2025-05-09 |
| 2023-12-31 | $219.64M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $219.66M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $219.71M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $189.11M 10-K · filed 2024-05-15 |
| 2022-12-31 | $189.11M 10-Q · filed 2023-02-02 |
| 2022-03-31 | $133.65M 10-K · filed 2023-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |